Shaky Q1 For Lupin But Upbeat On FDA Generics Reform, Biosimilars

Lupin reported a weak first quarter, but the management sees "tremendous upside" in opportunities arising from the US FDA’s recent initiatives to encourage generic competition. A build-up also appears on the cards for biosimilars, where the company now has a “financing partner” for a project.